Fumihiko Hattori
Fujita Health University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Fumihiko Hattori.
The Journal of Infectious Diseases | 2018
Hiroyuki Hiramatsu; Ryota Suzuki; Arisa Nagatani; Hiroko Boda; Masafumi Miyata; Fumihiko Hattori; Hiroki Miura; Ken Sugata; Shigeki Yamada; Satoshi Komoto; Koki Taniguchi; Masaru Ihira; Naoko Nishimura; Takao Ozaki; Tetsushi Yoshikawa
Background This study was conducted to assess the transmissibility of rotavirus vaccine strains after rotavirus vaccination in a neonatal intensive care unit (NICU). Methods Pentavalent (RV5) or monovalent (RV1) rotavirus vaccine was administered to infants admitted to the NICU. Nineteen vaccinated infants and 49 unvaccinated infants whose beds were located in close proximity to the vaccinated infants were enrolled in this study. Dissemination and fecal shedding of vaccine viruses within the NICU were examined using real-time reverse transcription-polymerase chain reaction. Results Shedding of the vaccine strain was detected in all 19 vaccinated infants. RV5 virus shedding started 1 day after the first vaccination and persisted for 8 days after the first vaccination, and viral shedding terminated by day 5 after administration of the second RV5 dose. The kinetics of RV1 virus shedding differed among vaccinated infants. The duration of RV1 virus shedding was longer after the first vaccination than after the second vaccination. In contrast to the vaccinated infants, no vaccine virus genomes were detected in any of the stool samples collected from the 49 unvaccinated infants. Conclusions This study is direct evidence of no transmission of rotavirus vaccine strains between vaccinated infants and unvaccinated infants in close proximity within a NICU.
Vaccine | 2017
Fumihiko Hattori; Hiroki Miura; Ken Sugata; Akiko Yoshikawa; Masaru Ihira; Yuichiro Yahata; Hajime Kamiya; Keiko Tanaka-Taya; Tetsushi Yoshikawa
OBJECTIVE Matched case control study was conducted to elucidate the effectiveness of the Oka/Biken vaccine immediately after implementation of the universal immunization program in Japan. METHODS Cases were laboratory confirmed varicella patient under 15years of age diagnosed at 14 designated pediatric clinics between September 2015 and September 2016. Controls were selected from patients who visited the same practice for different reasons as the varicella case within 2weeks. Swab samples were collected from varicella suspected patients and molecular diagnostic assays were used to confirm varicella cases. Matched odds ratio were used to calculate vaccine effectiveness (VE). RESULTS Varicella zoster virus DNA was detected in 183 (81.3%) of 225 suspected cases. One sample was excluded because it was positive for the Oka vaccine strain (182/225, 80.9%). Three hundred twenty-three control subjects were enrolled. The effectiveness of 1 dose of the Oka/Biken vaccine compared with no vaccine was 76.7% (95% confidence interval [CI]: 58.6-86.9%; P<0.001). The effectiveness of 2 doses of the Oka/Biken vaccine was 94.2% (95% CI: 85.7-97.6%; P<0.001). After adjusting for potential confounding effects, the adjusted VE of 1 and 2 doses of varicella vaccine were 76.9% (95% CI: 58.1-87.3%; P<0.001) and 94.7% (95% CI: 86.0-98.0%; P<0.001), respectively. CONCLUSIONS VE of one dose of Oka/Biken varicella vaccine was insufficient to control varicella. Therefore, two doses of Oka/Biken varicella vaccine is significant for controlling varicella in Japan.
Transplant Infectious Disease | 2018
Hiroki Miura; Yoshiki Kawamura; Fumihiko Hattori; Makito Tanaka; Kazuko Kudo; Masaru Ihira; Hiroshi Yatsuya; Yoshiyuki Takahashi; Seiji Kojima; Tetsushi Yoshikawa
We sought to determine whether late‐phase human herpesvirus 6B (HHV‐6B) infection in hematopoietic stem cell transplant (HSCT) recipients was associated with serious outcomes and mortality.
Pediatrics International | 2018
Fumihiko Hattori; Yoshiki Kawamura; Jun-ichi Kawada; Seiji Kojima; Jun Natsume; Koichi Ito; Shinji Saito; Yoshiro Kitagawa; Akihisa Okumura; Tetsushi Yoshikawa
Rotavirus can, rarely, cause severe complications such as encephalopathy/encephalitis, myocarditis, sudden death, urinary stone, and gastrointestinal (GI) bleeding; and the incidence of these severe complications remains unclear. Additionally, it has not been determined whether rotavirus (RV) vaccine could reduce cases of severe complications or not.
Journal of Medical Virology | 2018
Hiroki Miura; Yoshiki Kawamura; Fumihiko Hattori; Kei Kozawa; Masaru Ihira; Tamae Ohye; Hiroki Kurahashi; Tetsushi Yoshikawa
The objectives of the work are to elucidate the incidence and virological findings of chromosomally integrated human herpesvirus 6 (ciHHV‐6) in Japanese population and to analyze an association between ciHHV‐6 and the clinical manifestation of exanthema subitum (ES). Real‐time polymerase chain reaction was performed to determine HHV‐6 DNA loads in 2347 cord blood samples from healthy neonates (cohort A), febrile children less than 5 years old (cohort B), and hematopoietic cell transplant recipients (cohort C). CiHHV‐6 was confirmed by detection of high copy numbers of viral DNA in somatic cells. The integration site was determined by fluorescent in situ hybridization analysis. In the ciHHV‐6 subjects of cohorts A and B, HHV‐6 antibody titers were measured, the history of ES was obtained, and the incidence of ES was compared with non–ciHHV‐6 children without primary HHV‐6B infection in the cohort B. CiHHV‐6 was detected in 14 (0.60%) of the 2347 samples: A (6/1006, 0.60%), B (6/790, 0.76%), and C (2/551, 0.36%). The integration sites were on chromosome 22q in seven cases, Yp in two cases, and 17q and Xp in one case. No past history of ES was observed in 11 of the 12 subjects. Nine children with ciHHV‐6 underwent serological analysis and were found to be positive for HHV‐6 IgG antibodies. Incidence of ES was statistically higher in the control subjects than the ciHHV‐6 subjects (P = 0.0039). In Japan, the frequency of ciHHV‐6 was 0.60%. A high incidence of ciHHV‐6A, specifically in chromosome 22, is a characteristic finding among the Japanese. CiHHV‐6 may interfere with the clinical symptoms of primary HHV‐6B infection.
Japanese Journal of Infectious Diseases | 2013
Kensei Gotoh; Naoko Nishimura; Suguru Takeuchi; Fumihiko Hattori; Kazuhiro Horiba; Mai Isaji; Yu Okai; Yasunori Ohshima; Haruki Hosono; Koji Takemoto; Yasushi Iwata; Kazumasa Nakane; Keiji Funahashi; Takao Ozaki
Japanese Journal of Infectious Diseases | 2014
Kazuhiro Horiba; Naoko Nishimura; Kensei Gotoh; Masahiro Kawaguchi; Suguru Takeuchi; Fumihiko Hattori; Mai Isaji; Yu Okai; Haruki Hosono; Koji Takemoto; Takao Ozaki
The Journal of the Japanese Association for Infectious Diseases | 2014
Takao Ozaki; Naoko Nishimura; Kensei Gotoh; Kazuhiro Horiba; Fumihiko Hattori; Suguru Takeuchi; Keiji Funahashi; Hironori Yoshii; Yoshinobu Okuno
日本小児科学会雑誌 | 2013
Naoko Nishimura; Takao Ozaki; Kensei Gotoh; Suguru Takeuchi; Fumihiko Hattori; Kazuhiro Horiba; Mai Isaji; Yu Okai; Yasunori Ohshima; Haruki Hosono; Koji Takemoto
The Journal of the Japanese Association for Infectious Diseases | 2014
Kazuhiro Horiba; Kensei Gotoh; Fumihiko Hattori; Suguru Takeuchi; Naoko Nishimura; Takao Ozaki; Kimiyasu Shiraki